A therapy with the kINPen® MED is a good treatment especially for chronic wounds like ulcus cruris or diabetic feet. Apart from that the kINPen® MED plasma jet is used for treatment of postoperative wounds and pathogen-induced skin disorders such as fungal infections, warts or acne.
The treatment with cold plasma supports wound healing and has an additional anti-bacterial effect. Plasma therapy may prove successful in cases where standard procedures like antiseptics, ointments, dressings or even surgical wound care do not show any effect. Clinical studies and observational studies by physicians demonstrate that many chronic wounds heal after several weeks of therapy with the kINPen® MED device.
The plasma jet is moved evenly over the skin areas to be treated with a speed of ca. 5 mm/s without any direct wound contact. The plasma combines different modes of action (UV radiation, reactive species, electromagnetic fields, short-term temperature increase). These different components of cold plasma have a strong anti-bacterial effect and simultaneously stimulate the regeneration of healthy tissue.
The intensity of the treatment is controlled via the treatment time and should amount to 30-60 s/cm².
The treatment can be performed in one-day to three-day intervals as long as there are no side effects. The overall duration of the cold plasma therapy depends on the individual wound conditions and the treatment frequency.
Treatment with the kINPen® MED has proven to be very well tolerated. So far no side effects or formation of resistances have been observed.
The treatment is performed without any wound contact and it does not cause any additional pain. Patients report that the cold plasma application feels like a breath of cool air. Many of them experience an alleviation of pain itching after the treatment.
Ask your attending physician whether a treatment with the kINPen® MED cold plasma device could be an option for you.
The application of cold physical plasmas in wound management has not been integrated into routine care yet. The kINPen® MED is currently used by hospitals and an increasing number of independent medical practices. Some health insurance companies are beginning to take over the treatment costs upon application.
The kINPen® MED device has been approved for the treatment of chronic, infected, and badly healing wounds and pathogen-induced disorders of the skin and dermal appendages. Excellent results were obtained in the treatment of diabetic foot syndrome, decubitus, ulcus cruris, tinea pedis, onychomycosis, acne vulgaris, folliculitis and driveline infections.
Clinical researchers are working intensively on the extension of the application areas. At the moment first investigations are underway to explore an application in dental medicine, ophthalmology and cancer therapy.
The kINPen® MED device is moved vertically across the affected wound area at a moderate speed of ca. 5 mm/s. The effective field of the plasma is ca. 1 cm². During the treatment the specified distance and hygiene are maintained by using a replaceable spacer.
Yes, cold plasma therapy has proven to be an effective supplement to standard wound care.
Due to its easy handling, the physician may delegate the application of the kINPen® MED device to medical staff who has received the necessary training.
Patients accept the treatment very well as it is contactless and painless. Many patients describe the application of the cold plasma as a kind of cool breeze and report a reduction of pain and itching after the treatment. Furthermore, no side effects have been observed so far.
The treatment intensity is determined via the treatment duration and should amount to about 30-60 s/cm².
The treatment may be performed every one to three days unless side effects are observed. The overall duration of the plasma therapy is determined by the respective wound conditions and the treatment frequency.
On average about 10 treatments are required per wound. However, the required number of treatments varies widely and depends entirely on the individual biological condition of wound and patient.
This question is currently still a subject of ongoing research. The current recommendation is to continue with the plasma treatment until granulation tissue formation starts. The plasma treatment should be continued if no further healing progress is observed.
Yes, necrotic wounds or wounds with fibrin coating first have to undergo debridement before the plasma treatment can be started.
The plasma treatment should be performed before the application of topical medication to avoid undesired interactions with antiseptics. For this reason it is recommended that the wound should be cleaned with NaCl.
No, the wound does not have to be dried before the treatment.
The sensitivity to the plasma depends on the cell division rate: cells with a short doubling time (prokaryotes) are more sensitive to the influence of the plasma than cells with a slow reproduction rate (eukaryotes). When applied to the biological effects induced by cold atmospheric pressure plasma this means: A low treatment intensity/exposure time of cold atmospheric pressure plasmas results in the stimulations of cells. A higher treatment intensity/exposure time results in deactivation/necrosis.
The application of the kINPen® MED device does not involve any consumables apart from the inert gas argon, which is used for the generation of the plasma.
The use of cold physical plasmas in wound management is not part of the standard coverage yet. At the moment there is no according billing code. However, the health insurance companies may agree to cover the costs upon application.